Autogene cevumeran
- Generic Name
- Autogene cevumeran
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2365453-34-3
- Unique Ingredient Identifier
- L8HDH9IB06
- Background
Autogene cevumeran is an mRNA-based cancer vaccine targeting an unspecified amount of tumour-associated antigens. It is being investigated for cancers.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
Phase 2
Recruiting
- Conditions
- Muscle Invasive Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 362
- Registration Number
- NCT06534983
- Locations
- 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸MSK Monmouth, Middletown, New Jersey, United States
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Phase 2
Recruiting
- Conditions
- Adenocarcinoma, Pancreatic Ductal
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT05968326
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸USC Norris Cancer Center, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath